MUFG Americas’s Sarepta Therapeutics SRPT Stock Holding History

MUFG Americas’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-220	Closed	-$36K	–	790
2018 Q3	$36K	Hold	220	–	–	﹤0.01%	564
2018 Q2	$29K	Hold	220	–	–	﹤0.01%	615
2018 Q1	$16K	Sell	220 -70	-24%	-$4.67K	﹤0.01%	696
2017 Q4	$16K	Buy	+290	New	+$15.4K	﹤0.01%	797
2013 Q3	–	Sell	-3,000	Closed	-$114K	–	1429
2013 Q2	$114K	Buy	+3,000	New	+$107K	﹤0.01%	1000

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MUFG Americas's SRPT Position: Q4 2018 in Review

MUFG Americas sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 220 shares — an estimated $36K sold.

MUFG Americas first reported a position in SRPT in Q2 2013 and held it in 5 quarters. The position peaked at $114K in Q2 2013. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

MUFG Americas reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
MUFG Americas sold 220 Sarepta Therapeutics shares in Q4 2018, an estimated $36K.
MUFG Americas first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 5 quarters.
MUFG Americas's Sarepta Therapeutics position peaked at $114K in Q2 2013.
335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on MUFG Americas's 13F filing for Q4 2018, filed 13 Feb 2019.